https://www.selleckchem.com/pr....oducts/piperlongumin
Seventy-eight low-risk DTC patients (female 70 [89.7%]; male 8 [10.3%]) aged from 18 to 78 years old with mean of 41.96 ± 13.42 years were enrolled in this study. In total, the treatment was successful in 96.2% of patients. There was no significant difference in treatment success among groups (P 0.05), while there was a significant association among administered activity and side effects. In low dose patients, only one patient complained from dry mouth; however, 11/39 patients who received high dose of iodine complained from
Like
Comment
Share
